Navidea Biopharmaceuticals Elects to Extend Evaluation Period for Option to License Parkinson's Disease Imaging Agent
16:00 EDT 26 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty
pharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that it has elected to continue
diligence through the end of July with A...
Other Sources for this Article
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr.
VP & CFO
More From BioPortfolio on "Navidea Biopharmaceuticals Elects to Extend Evaluation Period for Option to License Parkinson's Disease Imaging Agent"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
